Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 26 | 2024 | 13102 | 1.900 |
Why?
|
| Small Cell Lung Carcinoma | 8 | 2023 | 388 | 1.670 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2024 | 5221 | 1.640 |
Why?
|
| Immunoconjugates | 3 | 2024 | 901 | 0.810 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 3086 | 0.760 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 841 | 0.760 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 420 | 0.600 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1681 | 0.390 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1622 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3597 | 0.300 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 13695 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 4034 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11524 | 0.260 |
Why?
|
| Mutation | 4 | 2023 | 29786 | 0.250 |
Why?
|
| Kidney Medulla | 3 | 2003 | 182 | 0.230 |
Why?
|
| Carcinoma, Large Cell | 1 | 2023 | 113 | 0.220 |
Why?
|
| Carcinoid Tumor | 1 | 2023 | 235 | 0.210 |
Why?
|
| Carbolines | 2 | 2020 | 265 | 0.200 |
Why?
|
| Membrane Transport Proteins | 3 | 2003 | 1028 | 0.200 |
Why?
|
| Urea | 2 | 2003 | 450 | 0.190 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 332 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 3479 | 0.170 |
Why?
|
| Mass Screening | 4 | 2022 | 5255 | 0.160 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 292 | 0.160 |
Why?
|
| Endogenous Retroviruses | 1 | 2018 | 112 | 0.150 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 806 | 0.130 |
Why?
|
| Humans | 31 | 2024 | 744343 | 0.130 |
Why?
|
| Ketoconazole | 1 | 2015 | 95 | 0.130 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 11031 | 0.120 |
Why?
|
| Interferons | 1 | 2018 | 706 | 0.120 |
Why?
|
| Urethral Neoplasms | 1 | 2014 | 40 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 6364 | 0.120 |
Why?
|
| Isoenzymes | 1 | 1998 | 1726 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 1791 | 0.110 |
Why?
|
| Homeostasis | 1 | 2003 | 3340 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 666 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2021 | 2265 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20129 | 0.090 |
Why?
|
| Kidney | 3 | 2003 | 7186 | 0.080 |
Why?
|
| Gene Expression | 1 | 2021 | 7799 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9239 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 9959 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2015 | 1826 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2018 | 2958 | 0.070 |
Why?
|
| Alleles | 1 | 2017 | 6933 | 0.070 |
Why?
|
| DNA | 1 | 2020 | 7301 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2021 | 4445 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 77449 | 0.060 |
Why?
|
| Pneumonectomy | 2 | 2023 | 1094 | 0.060 |
Why?
|
| Kidney Concentrating Ability | 1 | 2003 | 41 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2003 | 349 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 323 | 0.050 |
Why?
|
| Angiotensins | 1 | 2003 | 151 | 0.050 |
Why?
|
| Lung | 1 | 2020 | 9856 | 0.050 |
Why?
|
| Uremia | 1 | 2003 | 201 | 0.050 |
Why?
|
| Trophoblasts | 1 | 2023 | 215 | 0.050 |
Why?
|
| Vasopressins | 1 | 2003 | 370 | 0.050 |
Why?
|
| Urine | 1 | 2003 | 370 | 0.050 |
Why?
|
| Cell Membrane Permeability | 1 | 2003 | 590 | 0.050 |
Why?
|
| Prognosis | 2 | 2022 | 29063 | 0.050 |
Why?
|
| Camptothecin | 1 | 2024 | 576 | 0.050 |
Why?
|
| Aged | 7 | 2022 | 163280 | 0.050 |
Why?
|
| Male | 10 | 2022 | 350118 | 0.050 |
Why?
|
| Adult | 5 | 2023 | 214055 | 0.040 |
Why?
|
| Technology | 1 | 2021 | 305 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2023 | 1663 | 0.040 |
Why?
|
| Female | 8 | 2024 | 380194 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2023 | 859 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 326 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 2018 | 138 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39050 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 801 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2000 | 3768 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 8863 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2021 | 10252 | 0.040 |
Why?
|
| Rats | 4 | 2003 | 24260 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 6895 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 876 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 804 | 0.040 |
Why?
|
| Middle Aged | 6 | 2021 | 213383 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 20822 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 1662 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 401 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 850 | 0.030 |
Why?
|
| United States | 2 | 2020 | 69872 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2000 | 5021 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2000 | 1341 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2024 | 2416 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2022 | 1928 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2021 | 1708 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2020 | 2234 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 2879 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 3689 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 8642 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1998 | 5179 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2000 | 2924 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2020 | 63114 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 1995 | 963 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1998 | 8301 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2000 | 12072 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 21683 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 40561 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2000 | 7722 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 5853 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7322 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10943 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 57776 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5720 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12788 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2023 | 12208 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2018 | 3743 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3616 | 0.020 |
Why?
|
| Animals | 5 | 2018 | 168757 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 2494 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1998 | 11366 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 5751 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2000 | 4320 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16689 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23338 | 0.010 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2000 | 178 | 0.010 |
Why?
|
| Luciferases | 1 | 2000 | 733 | 0.010 |
Why?
|
| Mice | 2 | 2003 | 81183 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13284 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 1723 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 1526 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 1730 | 0.010 |
Why?
|
| Dogs | 1 | 2000 | 3912 | 0.010 |
Why?
|
| Diuresis | 1 | 1995 | 116 | 0.010 |
Why?
|
| Models, Structural | 1 | 1995 | 361 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 18111 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 5892 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 85781 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1995 | 1246 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3772 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 2050 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1995 | 957 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 1950 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 2839 | 0.010 |
Why?
|
| Oocytes | 1 | 1995 | 1187 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 12797 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 5867 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 4894 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 15997 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1995 | 3748 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6622 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 13815 | 0.000 |
Why?
|
| Models, Biological | 1 | 1995 | 9583 | 0.000 |
Why?
|
Concepts
(150)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(33)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_